About this Research Topic
Various strategies have been explored to improve efficacy and safety, including combining immunotherapy with chemotherapy, anti-angiogenic drugs, immune modulators, PARP inhibitors, and other therapeutic agents such as antibody-drug conjugates (ADCs), nanocarrier drug delivery systems, epigenetic modulators, MEK inhibitors, BET bromodomain inhibitors (BBDIs), and adenosine signaling pathway inhibitors. Additionally, factors such as PD-L1 expression, tumor-infiltrating lymphocyte (TIL) density, tumor mutation burden (TMB), and mismatch repair (MMR) have been identified as predictive biomarkers for immunotherapy response, providing a basis for developing personalized immunotherapy strategies and improving clinical benefits in TNBC.
Through an in-depth exploration of this Research Topic, our goal is to provide scientific evidence and clinical guidance for precision immunotherapy in triple-negative breast cancer. By developing more personalized, efficient, and safe treatment approaches, we aim to improve therapeutic outcomes and quality of life for patients with TNBC.
We welcome the submission of Original Research and Review articles, including but not limited to:
1) Regulatory mechanisms of immune cells and immune signaling pathways specific to TNBC.
2) Identification of immune-related biomarkers in TNBC patients and exploration of their potential roles in precision immunotherapy.
3) Development of precise immunotherapeutic strategies for TNBC, such as tumor vaccines, CAR-T cell therapy, etc.
4) Evaluation of more precise immunotherapy regimens for efficacy and safety in TNBC patients.
5) Investigation of immune evasion mechanisms in TNBC and strategies to overcome them.
6) Research on personalized treatment strategies, including predictive models based on genetics and immune histology.
7) Combination approaches of immunotherapy with other treatment modalities to enhance efficacy and alleviate adverse reactions.
8) Application of novel technologies such as nanocarrier drug delivery systems to facilitate precision immunotherapy for TNBC.
9) Cost-effectiveness analysis of immunotherapy to promote its sustainable development in the treatment of TNBC.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Keywords: Precision Immunotherapy, Triple-Negative Breast Cancer, Personalized Strategies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.